DBS for Treatment Resistant Depression

NCT ID: NCT01983904

Last Updated: 2019-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the effects of sub-callosal cingulate (SCC) deep brain stimulation (DBS) in patients with treatment resistant depression (TRD).

The working hypotheses are that long pulse-width DBS applied to the SCC region will lead to improvements in TRD patients, and specific neuroimaging biomarkers will correlate with response to DBS; the functional recovery will be enhanced with concurrent cognitive behavioural therapy (CBT).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim is to collect data on prediction, optimization and augmentation of DBS for TRD and develop tools for DBS surgery. It is a biological pilot study designed to provide informative data for future work.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Treatment-Resistant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Long Pulse Width

deep brain stimulation with short \& long pulse width

Group Type EXPERIMENTAL

deep brain stimulation with short & long pulse width

Intervention Type DEVICE

surgical implantation for bilateral electrodes and stimulation using short and long pulse width

Short Pulse Width

deep brain stimulation with short \& long pulse width

Group Type EXPERIMENTAL

deep brain stimulation with short & long pulse width

Intervention Type DEVICE

surgical implantation for bilateral electrodes and stimulation using short and long pulse width

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

deep brain stimulation with short & long pulse width

surgical implantation for bilateral electrodes and stimulation using short and long pulse width

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 20-70
* diagnosis of major depressive (MDD)or bipolar disorder(BP)determined independently by 2 study psychiatrists
* current major depressive episode of \>1 year duration, treatment-resistant (meaning failure to respond to 4 different classes of antidepressants, including augmentation or combination strategies with lithium, atypical antipsychotics, anticonvulsants, antidepressants, evidence-based psychotherapy, CBT, or electroconvulsive treatment despite adequate dosage, duration and compliance)
* minimum score of 20 (out of 52) on the 17 item Hamilton Depression Rating Scale (HDRS)
* resident of Alberta, Canada, covered by Alberta Health

Exclusion Criteria

* other Axis I psychiatric disorders including schizophrenia, psychosis, active suicidal ideation over previous 6 months
* cerebrovascular risk factors, previous stroke, head injury and neurodegenerative disorders, pregnancy, medical and general contraindications for DBS surgery (e.g. cardiac pacemaker/defibrillator)
* age \>70
* diabetes
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Calgary

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zelma Kiss

Associate Professor, Neurosurgery; Director Clinician Investigator Program

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zelma H Kiss, MD PhDFRCSC

Role: PRINCIPAL_INVESTIGATOR

University of Calgary, Department of Clinical Neurosciences

Rajamannar Ramasubbu, MD MRCP FRCP

Role: PRINCIPAL_INVESTIGATOR

University of Calgary, Department of Psychiatry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Calgary & Alberta Health Services, Foothills Medical Centre

Calgary, Alberta, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Ramasubbu R, Brown EC, Mouches P, Moore JA, Clark DL, Molnar CP, Kiss ZHT, Forkert ND. Multimodal imaging measures in the prediction of clinical response to deep brain stimulation for refractory depression: A machine learning approach. World J Biol Psychiatry. 2024 Mar;25(3):175-187. doi: 10.1080/15622975.2023.2300795. Epub 2024 Jan 17.

Reference Type DERIVED
PMID: 38185882 (View on PubMed)

Ramasubbu R, Clark DL, Golding S, Dobson KS, Mackie A, Haffenden A, Kiss ZH. Long versus short pulse width subcallosal cingulate stimulation for treatment-resistant depression: a randomised, double-blind, crossover trial. Lancet Psychiatry. 2020 Jan;7(1):29-40. doi: 10.1016/S2215-0366(19)30415-8.

Reference Type DERIVED
PMID: 31860455 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-20948

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

DBS for TRD With the Medtronic Summit RC+S
NCT04106466 ACTIVE_NOT_RECRUITING NA